Target intelligence / Profile preview

Neuronal pentraxin receptor (NPTXR)

Target
NPTXR
Molecular classification
Receptor, Type-II transmembrane glycoprotein, Member of the pentraxin protein family
01

Overview

Neuronal pentraxin receptor (NPTXR) is a type-II transmembrane glycoprotein that belongs to the pentraxin family, with structural homology to other neuronal pentraxins such as NPTX1 and NPTX2. It is primarily expressed in brain tissue and functions as a synaptic organizer, stabilizing and clustering postsynaptic neurotransmitter receptors, especially AMPA receptors, thereby contributing to synaptic plasticity. NPTXR forms glycosylated, disulfide-linked oligomers at the synaptic membrane, and its activity is critical for synapse formation and homeostatic plasticity. Variations in NPTXR levels in cerebrospinal fluid and serum have been associated with synaptic dysfunction in Alzheimer’s disease, making it a promising biomarker in neurodegenerative disease settings. The receptor may also be aberrantly expressed in some neuroendocrine tumors, such as small cell lung cancer, and participate in the neuronal uptake of specific toxins (e.g., taipoxin). No approved therapies directly target NPTXR, although its modulatory role at synapses makes it a theoretical therapeutic candidate for neurodegeneration and neuro-oncology.

Other names
NPTXRNPRneuronal pentraxin receptor
02

Mechanism of action

NPTXR mediates synaptic transport or clearance of exogenous molecules (e.g., taipoxin); participates in clustering and stabilization of AMPA receptors at excitatory synapses

03

Biological functions

Clustering, patterning, and stabilizing postsynaptic ligands (especially AMPA receptors)Regulation of synaptic plasticitySynaptic activity and synapse formationHomeostatic synaptic functionPossible neuronal uptake and synaptic clearance (e.g., uptake of exogenous molecules such as taipoxin)
04

Disease associations

Neurodegenerative disease (e.g., Alzheimer’s disease)Small cell lung cancer (neuroendocrine tumors)
05

Safety considerations

Aberrant expression in small cell lung cancer may render cells sensitive to toxins like taipoxinModulation of synaptic activity could carry risks if targeted therapeutically, especially in the context of neurodegeneration (inference based on function)
06

Interacting drugs

taipoxin (snake venom toxin)
07

Biomarkers

CSF and serum levels of NPTXR as biomarkers for Alzheimer’s disease and synaptic activityCorrelation with amyloid-β, total tau, and phosphorylated tau in AD

Beyond the preview

Go deeper on Neuronal pentraxin receptor (NPTXR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuronal pentraxin receptor (NPTXR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call